Skip to content

The efficacy and safety of small dose oxycodone in preventing shivering during cesarean section under epidural anesthesia:a double bind controlled trial

The efficacy and safety of small dose oxycodone in preventing shivering during cesarean section under epidural anesthesia:a double bind controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17013960
Enrollment
Unknown
Registered
2017-12-15
Start date
2017-12-14
Completion date
Unknown
Last updated
2018-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

shivering during cesarean section under epidural anesthesia

Interventions

group O:iv oxycodone
group T:iv tramadol
group C:iv NS

Sponsors

The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. The ASA I-II; 2. Aged between 18 and 45 years; 3. Full-term single pregnant woman; 4. Pregnant or authorized person write informed consent.

Exclusion criteria

Exclusion criteria: 1. heart disease (congenital heart disease, acquired heart disease); 2. pregnancy-induced hypertension syndrome; 3. fetal distress; 4. drug allergy; 5. hyperthyroidism; 6. Parkinson's disease; 7. BMI =28kg/m2; 8. Lung disease (specifically pulmonary infection, emphysema, chronic obstructive pulmonary disease, etc.); 9. renal function damage (BUN and/or Cr> upper limit of normal); 10. liver function damage (ALT and/or AST>1.5 times normal reference range); 11. suffering from mental, neurological diseases, or can not properly express the wishes of patients; 12. The patients were treated with sedative and analgesic drugs for a long time; 13. coagulation disorders (PT / APTT higher than the upper limit of the reference value); 14. Chronic constipation; 15. Simultaneous use of monoamine oxidase inhibitor or 2 weeks of renal function injury; 16. participants have been also involving in other drug clinical trials during the study.

Design outcomes

Primary

MeasureTime frame
The incidence and grades of shivering;apgar score;

Secondary

MeasureTime frame
heart reat;blood presure;pulse oxygen saturation;nausea and vomiting;drowsiness;pruritus;level of anesthesia;evaluation of visceral pain;temperature;

Countries

China

Contacts

Public ContactHan Lin

The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

nanlinhannansh@qq.com+86 15868710831

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026